Quality Systems

How single-use medical device reprocessing saves hospitals $495.5 million, cuts CO2 emissions by 125 million pounds, and drives circular economy adoption in healthcare — based on 2025 AMDR industry data, peer-reviewed lifecycle assessments, Cardinal Health and Stryker sustainability programs, EU MDR remanufacturing regulations, and the regulatory framework governing reprocessed devices.

A practical guide to the most common notified body technical file deficiencies under EU MDR — clinical data gaps, disjointed risk management, incomplete equivalence claims, weak PMS integration — plus how Implementing Regulation (EU) 2026/977 changes NB assessment timelines and what manufacturers must do to prepare for conformity assessment review.

A data-driven analysis of FDA medical device warning letter trends from 2024 through early 2026, covering the most common violations (CAPA, design controls, complaint handling), QMSR enforcement shifts since February 2026, notable enforcement actions against Beta Bionics, Abbott, Medline, and Philips, and practical compliance strategies for medical device manufacturers.

How the Department of Justice's record $6.8 billion False Claims Act enforcement in FY2025 impacts medical device companies — National Fraud Enforcement Division, Health Care Fraud Data Fusion Center using AI analytics, West Coast Strike Force, Anti-Kickback Statute compliance, whistleblower qui tam risks, and what manufacturers, distributors, and executives must do to reduce exposure in the most aggressive healthcare fraud enforcement environment in US history.

How to deploy cybersecurity patches to fielded medical devices while maintaining MDR conformity, FDA Section 524B postmarket obligations, and Cyber Resilience Act vulnerability handling timelines — covering risk-based triage, change control classification, coordinated disclosure integration with PSIRT, and the operational QMS workflow from vulnerability detection to verified field deployment.

How to validate adhesive bonding processes for medical devices — covering ISO 13485 Clause 7.5.6 and FDA QMSR requirements, UV curing and epoxy bonding process variables, IQ/OQ/PQ protocols, critical process parameters, surface preparation controls, adhesive chemistry selection (cyanoacrylate, UV-curable, epoxy, silicone), destructive testing strategy, revalidation triggers, and ongoing monitoring under FDA and EU MDR.

How to lock down antibody clones, manage lot-to-lot bridging studies, and maintain immunoassay performance across manufacturing campaigns — covering recombinant vs hybridoma strategies, critical quality attribute monitoring, bridging study design, and regulatory expectations under FDA QMSR, ISO 13485, and EU IVDR.

How to qualify battery cell suppliers and design battery packs for portable medical devices — covering lithium-ion chemistry selection (NMC, LFP, LCO, LTO), IEC 62133-2 and UN 38.3 compliance, Battery Management System requirements, FDA QMSR traceability, EU Battery Regulation due diligence, conflict minerals sourcing, lot-to-lot cell matching, incoming inspection, quality agreement structure, and dual-sourcing strategies for infusion pumps, ventilators, wearable monitors, and other Class II/III portable medical devices.

How to source biological specimen raw materials — human serum, plasma, urine, CSF, and tissue-derived matrices — for IVD calibrator and control manufacturing, including donor qualification, viral testing, traceability, TSE/BSE compliance, lot-to-lot consistency, and regulatory requirements under FDA 21 CFR 610, EU IVDR, and ISO 13485.

How to establish metrological traceability of calibrators and controls for in vitro diagnostic kits — covering ISO 17511:2020 calibration hierarchy models, JCTLM reference materials, WHO international standards, certified reference materials, commutability assessment, measurement uncertainty budgeting, value assignment protocols, and regulatory expectations under FDA, EU IVDR, and ISO 13485.

How to structure RACI matrices in CDMO quality agreements for sub-tier supplier control — defining who is responsible, accountable, consulted, and informed across OEM, CDMO, and sub-tier suppliers under ISO 13485, FDA QMSR, and EU MDR.

How to qualify and control coatings and surface treatment suppliers for medical devices — covering PVD, passivation, anodizing, DLC, plasma treatment, and antimicrobial coatings, with guidance on supplier audit, process validation (IQ/OQ/PQ), ASTM and ISO specification control, dimensional impact planning, biocompatibility evidence, quality agreement structure, and ongoing monitoring under FDA QMSR, ISO 13485, and EU MDR.

How to qualify a contract cleanroom assembly vendor for medical device manufacturing — cleanroom classification matching, environmental monitoring verification, gowning qualification, quality agreement requirements, audit approach, and ongoing oversight under ISO 13485, FDA QMSR, and EU MDR.

How to qualify a contract packaging vendor for medical device manufacturing — ISO 11607 validation capabilities, sterile barrier system expertise, seal process controls, labeling compliance, sterilization coordination, quality agreement requirements, and ongoing vendor oversight under ISO 13485, FDA QMSR, and EU MDR.

How to build and operate a quality management system for depot repair of reusable medical device capital equipment — receiving and triage, decontamination and biohazard protocols, diagnostic testing, repair and rework controls, calibration traceability, nonconformance handling, return-to-service release criteria, documentation requirements under FDA QMSR and ISO 13485, and audit readiness for depot service facilities.

How to qualify and manage enzyme suppliers for PCR and RT-qPCR in vitro diagnostic kits — covering Taq polymerase, hot-start variants, reverse transcriptase, lot-to-lot testing protocols, incoming acceptance specifications, stability requirements, change notification, and regulatory expectations under FDA QMSR, ISO 13485, and EU IVDR.

How to determine whether your medical device maintenance, repair, or modification activity is FDA-defined servicing or remanufacturing — the 6 guiding principles from the May 2024 final guidance, the decision flowchart, automatically-classified activities, software change rules, documentation requirements, and regulatory exposure for OEMs, third-party servicers, and hospital HTM teams.

How to build a complete traceability system for field service on software-enabled medical devices — electronic service records, software version and configuration tracking, firmware update logs, audit trail requirements under 21 CFR Part 11, traceability for installed base management, complaint-to-service-record linkage, and FDA inspection readiness under QMSR and ISO 13485 Clause 7.5.9.

How to prepare an IVD CDMO technology transfer readiness package — documentation requirements, process validation ownership, quality agreement structure, analytical method transfer, regulatory filing strategy, and risk mitigation under FDA 21 CFR 820/QMSR, ISO 13485, and EU IVDR.

How to transfer a legacy medical device from in-house or incumbent manufacturing to a CDMO — DMR and DDF handoff, tacit knowledge capture, gap analysis between equipment sets, first article inspection, process validation requalification, change control under FDA QMSR and ISO 13485, regulatory notification strategy, and timeline planning.